Shining on Major News : TIBCO Software (NASDAQ:TIBX), Youku Tudou (NYSE:YOKU), Apple Inc. (NASDAQ:AAPL), Concert Pharmaceuticals (NASDAQ:CNCE), KB Financial Group, Inc. (NYSE:KB),

TIBCO Software Inc. (NASDAQ:TIBX) was gaining Wednesday following reports that private equity firms are competing to buy the business software company. Vista Equity Partners and Thomas Bravo are a part of a small group of private equity firms vying for the opportunity to acquire Tibco, according to Reuters. TIBCO Software Inc. (NASDAQ:TIBX) belongs to Technology sector. Its net profit margin is 7.30% and weekly performance is -2.41%. On last trading day company shares ended up $20.26. TIBCO Software Inc. (NASDAQ:TIBX) distance from 50-day simple moving average (SMA50) is -1.28%.

Youku Tudou Inc (NASDAQ:YOKU) has received a consensus rating of “Hold” from the seventeen brokerages that are presently covering the company, AR Network reports. Two analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. Youku Tudou Inc. (NYSE:YOKU) shares advanced 0.11% in last trading session and ended the day at $18.08. YOKU Gross Margin is 19.10% and its return on assets is -5.40%. Youku Tudou Inc. (NYSE:YOKU) quarterly performance is -17.78%.

Apple Inc. (NASDAQ:AAPL) started selling its latest smartphone iPhone 6 and iPhone 6 Plus just last Friday, however, user complaints have started pouring in that the new devices bend under pressure. Apple Inc. (NASDAQ:AAPL) belongs to Consumer Goods sector. Its net profit margin is 21.60% and weekly performance is 0.17%. On last trading day company shares ended up $101.75. Apple Inc. (NASDAQ:AAPL) distance from 50-day simple moving average (SMA50) is 3.26%.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced that it has initiated a Phase 1 clinical trial of CTP-730, a novel product candidate that is being developed under its strategic collaboration with Celgene Corporation. Concert will conduct the randomized, double-blind, single ascending dose Phase 1 clinical trial designed to assess the safety, tolerability and pharmacokinetics of CTP-730. The study is expected to enroll up to 40 healthy subjects. The Phase 1 clinical program will also evaluate multiple ascending doses of CTP-730 and is expected to be completed in 2015. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) ended the last trading day at $13.94. Company weekly volatility is calculated as 4.98% and price to cash ratio as 2.55. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) showed a weekly performance of 1.09%.

KB Financial Group, Inc. (NYSE:KB)’s board dismissed the company’s top executive after he refused to step down following his suspension by South Korean regulators. The board of the nation’s second-largest financial group by market value agreed to remove Lim Young Rok, 59, from his chairman and chief executive officer posts at a meeting late yesterday, Seoul-based KB Financial said in a statement. His dismissal will take effect immediately to ensure “early stabilization and business normalization,” it said. KB Financial Group, Inc. (NYSE:KB) shares advanced 2.13% in last trading session and ended the day at $38.78. KB return on assets is 0.50%. KB Financial Group, Inc. (NYSE:KB) quarterly performance is 13.39%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone